Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna shares fell 2% in ...

Goldman Sachs updated its Sharpe Ratio basket, a list of 50 stocks with the highest expected risk-adjusted returns in the ...

The S&P 500 and Nasdaq added to their all-time highs at midday as investors anticipated more U.S. trade agreements ahead.

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Read more here.

Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) shares fell 2.2% Thursday as the company confirmed it is seeking outside investment to support its late-stage vaccine programs. The move underscores the biotech ...

Goldman Sachs analyst Salveen Richter downgrades Moderna from Buy to Neutral and lowers the price target from $99 to $51. The analyst expects Moderna to report product revenue at the low end of ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (BRSE:0QF) from Buy to Neutral. There are 1,448 funds or institutions reporting positions in Moderna ...

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna shares (MRNA) fell 2% in ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (WBAG:MRNA) from Buy to Neutral. There are 1,449 funds or institutions reporting positions in Moderna ...